Literature DB >> 30586521

Progress in BRCA-Mutated Ovarian Cancer.

David R Spriggs1, Dan L Longo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30586521     DOI： 10.1056/NEJMe1812644

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  Acquired multiple secondary BRCA2 mutations upon PARPi resistance in a metastatic pancreatic cancer patient harboring a BRCA2 germline mutation.

Authors:  Haitao Tao; Sisi Liu; Di Huang; Xiao Han; Xue Wu; Yang W Shao; Yi Hu
Journal:  Am J Transl Res       Date:  2020-02-15       Impact factor: 4.060

2.  Identification of a Prognostic Signature Associated With DNA Repair Genes in Ovarian Cancer.

Authors:  Hengzi Sun; Dongyan Cao; Xiangwen Ma; Jiaxin Yang; Peng Peng; Mei Yu; Huimei Zhou; Ying Zhang; Lei Li; Xiao Huo; Keng Shen
Journal:  Front Genet       Date:  2019-09-12       Impact factor: 4.599

3.  PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.

Authors:  Patrycja Gralewska; Arkadiusz Gajek; Agnieszka Marczak; Michał Mikuła; Jerzy Ostrowski; Agnieszka Śliwińska; Aneta Rogalska
Journal:  Int J Mol Sci       Date:  2020-12-19       Impact factor: 5.923

4.  Focal Serous Tubal Intra-Epithelial Carcinoma Lesions Are Associated With Global Changes in the Fallopian Tube Epithelia and Stroma.

Authors:  Jingni Wu; Yael Raz; Maria Sol Recouvreux; Márcio Augusto Diniz; Jenny Lester; Beth Y Karlan; Ann E Walts; Arkadiusz Gertych; Sandra Orsulic
Journal:  Front Oncol       Date:  2022-03-21       Impact factor: 5.738

Review 5.  PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues.

Authors:  Pooja Murthy; Franco Muggia
Journal:  Cancer Drug Resist       Date:  2019-09-19

6.  Plasma Protein Biomarkers Associated with Higher Ovarian Cancer Risk in BRCA1/2 Carriers.

Authors:  Hee-Sung Ahn; Jung Yoon Ho; Jiyoung Yu; Jeonghun Yeom; Sanha Lee; Soo Young Hur; Yuyeon Jung; Kyunggon Kim; Youn Jin Choi
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.